Dr. Bunker is CEO and cofounder of Z-Alpha. Prior to Z-Alpha, Dr. Bunker was a co-founder of Zentalis Pharmaceuticals and previously served as Chief Science Officer (CSO) and initial Chief Operating Officer (COO) of the Company. He led R&D at Zentalis from the Company’s formation until his departure. Prior to his departure, Dr. Bunker led the out-licensing of the internal proprietary ADC platform to Immunome, including clinical compound IM-1021. In addition to leading R&D, Dr. Bunker has led and overseen several departments as COO, including Drug Supply and Manufacturing, Regulatory Affairs, Quality Assurance, Translational Science, Operations, Program Management, Commercial Development, and Human Resources. Prior to Zentalis, he co-founded Kalyra Pharmaceuticals, a small molecule drug discovery and development company focused on creating best-in-class medicines. Previously, he was a member of Pfizer’s drug discovery research group, as part of the Medicinal Chemistry Department, where he specialized in multiple therapeutic areas, including oncology, diabetes, antivirals, and ophthalmology. Earlier in his career, Dr. Bunker conducted postdoctoral research at The Scripps Research Institute under the direction of Dr. Dale Boger. He received his Ph.D. in Organic Chemistry from the University of California, San Diego under the direction of Dr. Joseph O’Connor and his Bachelor of Science in Chemistry from Arizona State University.